#ES­MO16: Boehringer drug flops on OS end­point; Medi­vir re­or­ga­nizes, cuts staff

Fresh on the heels of an em­bar­rass­ing set­back with a lethal can­cer drug in-li­censed from Han­mi, Boehringer In­gel­heim re­port­ed over the week­end that nintedanib flunked the co-pri­ma­ry end­point for over­all sur­vival in treat­ing metasta­t­ic col­orec­tal can­cer. The drug arm did beat out best sup­port­ive care for re­duc­ing the risk of pro­gres­sion. Boehringer ex­ecs say they’re still study­ing the da­ta, which was re­viewed at ES­MO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER